Edgewood Oncology
PrivateLast Round
Series A
Mar 25, 2024
Total Funding Raised
$20M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Edgewood Oncology is a biotechnology company developing BTX-A51, a small molecule, multi-kinase inhibitor for patients with hematologic malignancies and genetically-defined solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Edgewood Oncology Comparables
Compare Edgewood Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CasInvent Pharma | 75% | |
| Prelude Therapeutics | 73% | |
| Syros Pharmaceuticals Inc | 71% | |
Edgewood Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 25, 2024 |
Edgewood Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alta Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors grew 68% MoM.
- May 11, 2026
Monthly visitors grew 128% MoM, from 255 to 582.
Edgewood Oncology Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Edgewood Oncology's valuation, stock price, and market status.